Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve participants with follicular lymphoma.
Epistemonikos ID: 2fb3c0f3d5e5a58315f4c2991cfa6e84b7e8bb91
First added on: May 17, 2024